RxDoctor Payments Data

Willie Pennick, MD

Family Medicine · Jacksonville, FLNPI 1568426302

Payments from drug & device makers

$3,919in general payments, 2019–2025

Across 185 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$758
  • Bayer$511
  • Pfizer$352
  • Boehringer Ingelheim$161
  • Astellas Pharma US Inc$157
  • plus $906 from 14 others

What the payments were for

  • Food & beverage$3,62993%
  • Education$2907%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,919 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$78,008
Medicare patients
156
Services billed
926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$97,120
EliquisApixaban78$59,379
JanuviaSitagliptin Phosphate48$59,152
JardianceEmpagliflozin62$46,501
Janumet XrSitagliptin Phos/Metformin Hcl33$32,604
Synjardy XrEmpagliflozin/Metformin Hcl23$22,543
LinzessLinaclotide24$17,625
EntrestoSacubitril/Valsartan11$16,318
MounjaroTirzepatide12$14,418
GlyxambiEmpagliflozin/Linagliptin21$11,791
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,083
RybelsusSemaglutide11$10,126
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro22$8,308
SynjardyEmpagliflozin/Metformin Hcl12$7,137
PremarinEstrogens, Conjugated14$6,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,074$107,24690 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Synjardy, Trijardy Xr$161$93,964136 claims
PfizerEliquis, Premarin$352$65,91892 claims
Lilly USA, LLCMounjaro$140$14,41812 claims
GSKTrelegy Ellipta$94$11,08311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →